Quality Standards for the Management of NAFLD: Consensus Recommendations from the British Association for the Study of the Liver (BASL) and British Society of Gastroenterology (BSG) NAFLD Special Interest Group

[1]  C. Canivet,et al.  Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events , 2022, Journal of Hepatology.

[2]  G. Marchesini,et al.  Non-alcoholic fatty liver disease: A patient guideline , 2021, JHEP reports : innovation in hepatology.

[3]  E. Giannini,et al.  Is there an ‘ideal’ diet for patients with NAFLD? , 2021, European journal of clinical investigation.

[4]  J. Aronson,et al.  Associations between statins and adverse events in primary prevention of cardiovascular disease: systematic review with pairwise, network, and dose-response meta-analyses , 2021, BMJ.

[5]  V. Wong,et al.  Defining comprehensive models of care for NAFLD , 2021, Nature Reviews Gastroenterology & Hepatology.

[6]  M. Friedrich-Rust,et al.  Easl Clinical Practice Guidelines (Cpgs) On Non-Invasive Tests For Evaluation Of Liver Disease Severity And Prognosis- 2020 Update. , 2021, Journal of hepatology.

[7]  P. Fariselli,et al.  Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease. , 2021, Journal of hepatology.

[8]  Yu Xu,et al.  Impact of diabetes on subclinical atherosclerosis and major cardiovascular events in individuals with and without non-alcoholic fatty liver disease. , 2021, Diabetes research and clinical practice.

[9]  V. Wong,et al.  Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis , 2021, Gut.

[10]  Q. Anstee,et al.  Embedding assessment of liver fibrosis into routine diabetic review in primary care , 2021, JHEP reports : innovation in hepatology.

[11]  B. Hanratty,et al.  The pathway to better primary care for chronic liver disease. , 2021, The British journal of general practice : the journal of the Royal College of General Practitioners.

[12]  A. Lonardo,et al.  Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials , 2021, Metabolites.

[13]  Q. Anstee,et al.  Implementation of a care bundle improves the management of patients with non-alcoholic fatty liver disease , 2021, Frontline Gastroenterology.

[14]  9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2021. , 2020, Diabetes care.

[15]  G. Targher,et al.  Sodium-Glucose Cotransporter-2 Inhibitors for Treatment of Nonalcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials , 2020, Metabolites.

[16]  C. Byrne,et al.  NAFLD, and cardiovascular and cardiac diseases: Factors influencing risk, prediction and treatment. , 2020, Diabetes & metabolism.

[17]  A. Sahu,et al.  Safety of metabolic and bariatric surgery in obese patients with liver cirrhosis: a systematic review and meta-analysis. , 2020, Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery.

[18]  Soon-Hee Lee,et al.  Cardiovascular outcomes with glucagon-like peptide 1 agonists and sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes: A meta-analysis , 2020, Cardiology journal.

[19]  J. Ludvigsson,et al.  Mortality in Biopsy-Confirmed Nonalcoholic Fatty Liver Disease , 2020, Gut.

[20]  P. Bossuyt,et al.  Prognostic accuracy of FIB‐4, NAFLD fibrosis score and APRI for NAFLD‐related events: A systematic review , 2020, Liver international : official journal of the International Association for the Study of the Liver.

[21]  E. Brunt.  Liver Biopsy Reliability in Clinical Trials: Thoughts from a Liver Pathologist. , 2020, Journal of hepatology.

[22]  T. Goeser,et al.  NAFLD and cardiovascular diseases: a clinical review , 2020, Clinical Research in Cardiology.

[23]  G. Koch,et al.  Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials. , 2020, Journal of hepatology.

[24]  G. Minuk,et al.  The impact of primary biliary cholangitis on non-alcoholic fatty liver disease , 2020, European journal of gastroenterology & hepatology.

[25]  Masahiro Ito,et al.  Incidence, predictive factors and severity of methotrexate-related liver injury in rheumatoid arthritis: a longitudinal cohort study , 2020, Rheumatology advances in practice.

[26]  M. Anvari,et al.  Bariatric surgery before, during, and after liver transplantation: a systematic review and meta-analysis. , 2020, Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery.

[27]  P. Bossuyt,et al.  Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: A systematic review and meta-analysis. , 2020, Journal of hepatology.

[28]  A. Fowell,et al.  Evaluation of a primary to secondary care referral pathway and novel nurse-led one-stop clinic for patients with suspected non-alcoholic fatty liver disease , 2020, Frontline Gastroenterology.

[29]  B. Hanratty,et al.  Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies , 2020, PLoS medicine.

[30]  F. Tacke,et al.  High Protein Intake Is Associated With Histological Disease Activity in Patients With NAFLD , 2020, Hepatology communications.

[31]  J. Neuberger,et al.  Adult liver transplantation: A UK clinical guideline - part 1: pre-operation , 2020, Frontline Gastroenterology.

[32]  M. Färkkilä,et al.  Drinking and Obesity: Alcoholic Liver Disease/Nonalcoholic Fatty Liver Disease Interactions , 2020, Seminars in Liver Disease.

[33]  K. Corey,et al.  Advanced fibrosis is associated with incident cardiovascular disease in patients with non‐alcoholic fatty liver disease , 2020, Alimentary pharmacology & therapeutics.

[34]  Xian-E Peng,et al.  Physical activity intervention for non-diabetic patients with non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials , 2020, BMC Gastroenterology.

[35]  N. Bhala,et al.  Association Between Fibrosis Stage and Outcomes of Patients with Non-Alcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis. , 2020, Gastroenterology.

[36]  Andrew A. Li,et al.  Inadequate Physical Activity and Sedentary Behavior Are Independent Predictors of Nonalcoholic Fatty Liver Disease , 2020, Hepatology.

[37]  Hongliang Li,et al.  Nonalcoholic Fatty Liver Disease , 2019, Hypertension.

[38]  E. Benjamin,et al.  Alcohol Use is Associated with Hepatic Steatosis Among Persons with Presumed Non-alcoholic Fatty Liver Disease. , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[39]  L. Adams,et al.  Lifestyle modification in NAFLD/NASH: Facts and figures , 2019, JHEP reports.

[40]  Robert P. Myers,et al.  Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials , 2019, Hepatology.

[41]  N. Sattar,et al.  Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adults , 2019, BMJ.

[42]  C. Murray,et al.  Mortality, morbidity, and risk factors in China and its provinces, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 , 2019, The Lancet.

[43]  A. Tsapas,et al.  Performance of Baveno VI and Expanded Baveno VI Criteria for Excluding High-Risk Varices in Patients With Chronic Liver Diseases: A Systematic Review and Meta-analysis. , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[44]  D. Thorburn,et al.  Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease. , 2019, Journal of hepatology.

[45]  W. Rosenberg,et al.  Cost-comparison analysis of FIB-4, ELF and fibroscan in community pathways for non-alcoholic fatty liver disease , 2019, BMC Gastroenterology.

[46]  Xuan Zhu,et al.  Systematic review with a meta-analysis: clinical effects of statins on the reduction of portal hypertension and variceal haemorrhage in cirrhotic patients , 2019, BMJ Open.

[47]  Elizabeth Morris,et al.  Association of Weight Loss Interventions With Changes in Biomarkers of Nonalcoholic Fatty Liver Disease , 2019, JAMA internal medicine.

[48]  P. Donnan,et al.  Intelligent Liver Function Testing (iLFT): A trial of automated diagnosis and staging of liver disease in Primary Care. , 2019, Journal of hepatology.

[49]  Brooks V. Udelsman,et al.  Risk factors and prevalence of liver disease in review of 2557 routine liver biopsies performed during bariatric surgery. , 2019, Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery.

[50]  D. Houghton,et al.  Barriers and Facilitators to Mediterranean Diet Adoption by Patients With Nonalcoholic Fatty Liver Disease in Northern Europe. , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[51]  F. Tacke,et al.  Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis , 2019, Hepatology.

[52]  M. Anvari,et al.  Complete Resolution of Nonalcoholic Fatty Liver Disease After Bariatric Surgery: A Systematic Review and Meta‐analysis , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[53]  R. Holman,et al.  A multidisciplinary approach to the management of NAFLD is associated with improvement in markers of liver and cardio-metabolic health , 2019, Frontline Gastroenterology.

[54]  V. de Lédinghen,et al.  Validation of Baveno VI Criteria for Screening and Surveillance of Esophageal Varices in Patients With Compensated Cirrhosis and a Sustained Response to Antiviral Therapy. , 2019, Gastroenterology.

[55]  E. Muradova,et al.  Bariatric surgery improves nonalcoholic fatty liver disease: a contemporary systematic review and meta-analysis. , 2019, Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery.

[56]  G. Svegliati-Baroni,et al.  Recommendations for Management and Treatment of Nonalcoholic Steatohepatitis , 2019, Transplantation.

[57]  Yoosoo Chang,et al.  Smoking and the Risk of Non-Alcoholic Fatty Liver Disease: A Cohort Study , 2018, The American Journal of Gastroenterology.

[58]  J. Sherriff,et al.  Ad Libitum Mediterranean and Low‐Fat Diets Both Significantly Reduce Hepatic Steatosis: A Randomized Controlled Trial , 2018, Hepatology.

[59]  M. Manns,et al.  Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. , 2018, Journal of hepatology.

[60]  W. Rosenberg,et al.  A Pragmatic Approach Identifies a High Rate of Nonalcoholic Fatty Liver Disease With Advanced Fibrosis in Diabetes Clinics and At‐Risk Populations in Primary Care , 2018, Hepatology communications.

[61]  D. Sinn,et al.  Validation of the Baveno VI and the expanded Baveno VI criteria to identify patients who could avoid screening endoscopy , 2018, Liver international : official journal of the International Association for the Study of the Liver.

[62]  M. Abecassis,et al.  Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases , 2018, Hepatology.

[63]  O. Franco,et al.  Association of dietary macronutrient composition and non-alcoholic fatty liver disease in an ageing population: the Rotterdam Study , 2018, Gut.

[64]  M. Heneghan,et al.  Palliative care in end‐stage liver disease: Time to do better? , 2018, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[65]  P. Schirmacher,et al.  EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. , 2018, Journal of hepatology.

[66]  D. Levy,et al.  Improved Diet Quality Associates With Reduction in Liver Fat, Particularly in Individuals With High Genetic Risk Scores for Nonalcoholic Fatty Liver Disease. , 2018, Gastroenterology.

[67]  Michael Charlton,et al.  The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases , 2018, Hepatology.

[68]  E. Feskens,et al.  Associations between dietary factors and markers of NAFLD in a general Dutch adult population , 2018, European Journal of Clinical Nutrition.

[69]  R. Hultcrantz,et al.  Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. , 2017, Journal of hepatology.

[70]  Introduction: Standards of Medical Care in Diabetes—2018 , 2017, Diabetes Care.

[71]  Mark Hudson,et al.  Guidelines on the management of abnormal liver blood tests , 2017, Gut.

[72]  L. Real,et al.  Changes in Liver Steatosis After Switching From Efavirenz to Raltegravir Among Human Immunodeficiency Virus–Infected Patients With Nonalcoholic Fatty Liver Disease , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[73]  J. B. Moore,et al.  Efficacy of dietary and physical activity intervention in non-alcoholic fatty liver disease: a systematic review , 2017, Proceedings of the Nutrition Society.

[74]  K. Irvine,et al.  Multimorbidity and polypharmacy in diabetic patients with NAFLD , 2017, Medicine.

[75]  V. Wong,et al.  Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta‐analysis , 2017, Hepatology.

[76]  J. Bosch,et al.  Effects of an intensive lifestyle intervention program on portal hypertension in patients with cirrhosis and obesity: The SportDiet study , 2017, Hepatology.

[77]  H. Poustchi,et al.  Non-alcoholic fatty liver disease (NAFLD) and 10-year risk of cardiovascular diseases. , 2017, Clinics and research in hepatology and gastroenterology.

[78]  M. Allison,et al.  Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis , 2016, The American Journal of Gastroenterology.

[79]  T. Kawaguchi,et al.  Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: A systematic review. , 2017, Journal of hepatology.

[80]  M. Pinzani,et al.  Validation of the Baveno VI criteria to identify low risk cirrhotic patients not requiring endoscopic surveillance for varices. , 2016, Journal of hepatology.

[81]  Amy Downing,et al.  High hospital research participation and improved colorectal cancer survival outcomes: a population-based study , 2016, Gut.

[82]  D. Crawford,et al.  Iron and non-alcoholic fatty liver disease , 2016, World journal of gastroenterology.

[83]  Jennifer H. Martin,et al.  Prevalence of medication discrepancies in patients with cirrhosis: a pilot study , 2016, BMC Gastroenterology.

[84]  Corrado Barbui,et al.  Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. , 2016, Journal of hepatology.

[85]  H. Tilg,et al.  EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. , 2016, Journal of hepatology.

[86]  K. Clément,et al.  Statins, antidiabetic medications and liver histology in patients with diabetes with non-alcoholic fatty liver disease , 2016, BMJ open gastroenterology.

[87]  J. Fallowfield,et al.  Clinically significant chronic liver disease in people with Type 2 diabetes: the Edinburgh Type 2 Diabetes Study , 2015, QJM : monthly journal of the Association of Physicians.

[88]  A. Sanyal,et al.  Drug-induced fatty liver disease: An overview of pathogenesis and management. , 2015, Annals of hepatology.

[89]  Marco Maggioni,et al.  Statin use and non-alcoholic steatohepatitis in at risk individuals. , 2015, Journal of hepatology.

[90]  N. Johnson,et al.  The benefits of exercise for patients with non-alcoholic fatty liver disease , 2015, Expert review of gastroenterology & hepatology.

[91]  S. Friedman,et al.  Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. , 2015, Gastroenterology.

[92]  F. Pattou,et al.  Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients. , 2015, Gastroenterology.

[93]  E. Bjornsson,et al.  Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. , 2015, Gastroenterology.

[94]  C. Fox,et al.  Sugar-sweetened beverage, diet soda, and fatty liver disease in the Framingham Heart Study cohorts. , 2015, Journal of hepatology.

[95]  Puneet Puri,et al.  Severity of nonalcoholic fatty liver disease and progression to cirrhosis are associated with atherogenic lipoprotein profile. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[96]  A. Burt,et al.  Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. , 2015, Journal of hepatology.

[97]  Mats Fredrikson,et al.  Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up , 2015, Hepatology.

[98]  Vincent Wai-Sun Wong,et al.  Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study , 2015, Gut.

[99]  Zhen Wang,et al.  Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[100]  Y. Ben-Shlomo,et al.  Life course trajectories of alcohol consumption in the United Kingdom using longitudinal data from nine cohort studies , 2015, BMC Medicine.

[101]  Gregory Traversy,et al.  Alcohol Consumption and Obesity: An Update , 2015, Current Obesity Reports.

[102]  A. Burroughs,et al.  Cost-effectiveness of non-invasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with chronic liver disease: systematic review and economic evaluation. , 2015, Health technology assessment.

[103]  J. Jónasson,et al.  Long term follow-up and liver-related death rate in patients with non-alcoholic and alcoholic related fatty liver disease , 2014, BMC Gastroenterology.

[104]  P. Bedossa.  Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease , 2014, Hepatology.

[105]  Emmanuel A Tsochatzis,et al.  Liver cirrhosis , 2014, The Lancet.

[106]  A. Canbay,et al.  Extrahepatic complications of nonalcoholic fatty liver disease , 2014, Hepatology.

[107]  A. Burt,et al.  Clinical but not histological factors predict long‐term prognosis in patients with histologically advanced non‐decompensated alcoholic liver disease , 2014, Liver international : official journal of the International Association for the Study of the Liver.

[108]  E. Bjornsson,et al.  Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. , 2013, Gastroenterology.

[109]  S. Verma,et al.  Predictive value of ALT levels for non‐alcoholic steatohepatitis (NASH) and advanced fibrosis in non‐alcoholic fatty liver disease (NAFLD) , 2013, Liver international : official journal of the International Association for the Study of the Liver.

[110]  H. Naci,et al.  Comparative benefits of statins in the primary and secondary prevention of major coronary events and all-cause mortality: a network meta-analysis of placebo-controlled and active-comparator trials , 2013, European journal of preventive cardiology.

[111]  G. Musso,et al.  Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials , 2012, Diabetologia.

[112]  Q. Anstee,et al.  How big a problem is non-alcoholic fatty liver disease? , 2011, BMJ : British Medical Journal.

[113]  A. McCullough,et al.  Smoking and severity of hepatic fibrosis in nonalcoholic fatty liver disease. , 2011, Journal of hepatology.

[114]  V. Wong,et al.  High prevalence of colorectal neoplasm in patients with non-alcoholic steatohepatitis , 2011, Gut.

[115]  A. Burt,et al.  Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease , 2022 .

[116]  D. Reboussin,et al.  Effect of a 12-Month Intensive Lifestyle Intervention on Hepatic Steatosis in Adults With Type 2 Diabetes , 2010, Diabetes Care.

[117]  E. Jackvony,et al.  Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis , 2010, Hepatology.

[118]  A. Abid,et al.  Soft drink consumption is associated with fatty liver disease independent of metabolic syndrome. , 2009, Journal of hepatology.

[119]  A. Sanyal,et al.  Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[120]  Z. Halpern,et al.  Role of leisure‐time physical activity in nonalcoholic fatty liver disease: A population‐based study , 2008, Hepatology.

[121]  Z. Halpern,et al.  Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): a population based study. , 2007, Journal of hepatology.

[122]  Robert J Volk,et al.  AUDIT-C as a brief screen for alcohol misuse in primary care. , 2007, Alcoholism, clinical and experimental research.

[123]  R. Hultcrantz,et al.  Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment. , 2007, Journal of hepatology.

[124]  T. Therneau,et al.  The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD , 2007, Hepatology.

[125]  O. Cummings,et al.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.

[126]  Richard Doll,et al.  Mortality in relation to smoking: 22 years' observations on female British doctors. , 1980, British medical journal.

[127]  Zhao-You Tang,et al.  Randomized controlled trial of screening for hepatocellular carcinoma , 2004, Journal of Cancer Research and Clinical Oncology.

[128]  Jasmine Schwartz,et al.  Hepatic Steatosis in Hepatitis C Virus Genotype 3 Infection: Does It Correlate with Body Mass Index, Fibrosis, and HCV Risk Factors? , 2004, Digestive Diseases and Sciences.

[129]  G. Marchesini,et al.  Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome , 2003, Hepatology.

[130]  G. Farrell.  Drugs and Steatohepatitis , 2002, Seminars in liver disease.

[131]  S. Grundy,et al.  National Cholesterol Education Program Third Report of the National Cholesterol Education Program ( NCEP ) Expert Panel on Detection , Evaluation , and Treatment of High Blood Cholesterol in Adults ( Adult Treatment Panel III ) Final Report , 2022 .

[132]  G. Brandi,et al.  Prevalence of and Risk Factors for Hepatic Steatosis in Northern Italy , 2000, Annals of Internal Medicine.